Top

Published in:

01-01-2014 | Anesthetic Techniques in Pain Management (D Wang, Section Editor)

Intrathecal Therapy for Chronic Pain: Current Trends and Future Needs

Authors: Salim M. Hayek, Michael C. Hanes

Published in: Current Pain and Headache Reports | Issue 1/2014

Abstract

The management of chronic pain continues to pose many challenges to healthcare providers. Intrathecal drug delivery systems (IDDS) provide an effective therapy for patients suffering from chronic pain intractable to medical management. However, the clinical growth of intrathecal therapy continues to face many challenges, and is likely underutilized secondary to its high-complexity and limited reimbursement. The clinical utility of IDDS remains limited by lack of prospective randomized, placebo-controlled studies. In addition, there remains a need to enhance physician knowledge on the pharmacodynamics and pharmacokinetics of intrathecal drug delivery and promote further research into this field and drug delivery modalities. The purpose of this article is to provide a comprehensive review of the determinants of successful intrathecal drug delivery with an emphasis on its use in noncancer pain.

Bier A. Atempts over Cocainisirung of the Ruckenmarkers [in German]. Deutsche Zeitschrift für Chirurgie. 1899;51:9.CrossRef

Kitagawa O. On spinal anesthesia with cocaine. Jpn Soc Surg. 1901;3:185–91.

Knight KH, Brand FM, McHaourab AS, Veneziano G. Implantable intrathecal pumps for chronic pain: highlights and updates. Croat Med J. 2007;48:22–34.PubMedCentralPubMed

Yaksh TL, Wilson PR, Kaiko RF, Inturrisi CE. Analgesia produced by a spinal action of morphine and effects upon parturition in the rat. Anesthesiology. 1979;51:386–92.PubMedCrossRef

Goldstein A, Lowney LI, Pal BK. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain. Proc Natl Acad Sci U S A. 1971;68:1742–7.PubMedCentralPubMedCrossRef

Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science. 1973;179:1011–4.PubMedCrossRef

Wang JK, Nauss LA, Thomas JE. Pain relief by intrathecally applied morphine in man. Anesthesiology. 1979;50:149–51.PubMedCrossRef

Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc. 1981;56:516–20.PubMed

Coombs DW, Saunders RL, Gaylor MS, Block AR, Colton T, Harbaugh R, et al. Relief of continuous chronic pain by intraspinal narcotics infusion via an implanted reservoir. JAMA. 1983;250:2336–9.PubMedCrossRef

10.

Auld AW, Maki-Jokela A, Murdoch DM. Intraspinal narcotic analgesia in the treatment of chronic pain. Spine. 1985;10:777–81.PubMedCrossRef

11.

Paice JA, Penn RD, Shott S. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage. 1996;11:71–80.PubMedCrossRef

12.

Penn RD, Paice JA. Chronic intrathecal morphine for intractable pain. J Neurosurg. 1987;67:182–6. doi:10.3171/jns.1987.67.2.0182.PubMedCrossRef

13.

Henry-Feugeas MC, Idy-Peretti I, Baledent O, Poncelet-Didon A, Zannoli G, Bittoun J, et al. Origin of subarachnoid cerebrospinal fluid pulsations: a phase-contrast MR analysis. Magn Reson Imaging. 2000;18:387–95.PubMedCrossRef

14.

Friese S, Hamhaber U, Erb M, Kueker W, Klose U. The influence of pulse and respiration on spinal cerebrospinal fluid pulsation. Invest Radiol. 2004;39:120–30. doi:10.1097/01.rli.0000112089.66448.bd.PubMedCrossRef

15.

Alperin N, Vikingstad EM, Gomez-Anson B, Levin DN. Hemodynamically independent analysis of cerebrospinal fluid and brain motion observed with dynamic phase contrast MRI. Magn Reson Med. 1996;35:741–54.PubMedCrossRef

16.

Stockman HW. Effect of anatomical fine structure on the flow of cerebropsinal fluid in the spinal subarachnoid space. J Biochem Eng. 2006;128:106–14.

17.

Degrell I, Nagy E. Concentration gradients for HVA, 5-HIAA, ascorbic acid, and uric acid in cerebrospinal fluid. Biol Psychiatry. 1990;27:891–6.PubMedCrossRef

18.

Bernards CM. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology. 2006;105:169–78.PubMedCrossRef

19.•

Hettiarachchi HD, Hsu Y, Harris Jr TJ, Penn R, Linninger AA, Hettiarachchi HD, et al. The effect of pulsatile flow on intrathecal drug delivery in the spinal canal. Ann Biomed Eng. 2011;39. A study that analyzed cerebrospinal fluid flow patterns using single photon emission computed tomography in a human spine model as a predictor for the deliveery patterns of intrathecal drugs.

20.

Bernards CM. Understanding the physiology and pharmacology of epidural and intrathecal opioids. Best Pract Res Clin Anaesthesiol. 2002;16:489–505.PubMedCrossRef

21.

Ummenhofer WC, Arends RH, Shen DD, Bernards CM. Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil. Anesthesiology. 2000;92:739–53.PubMedCrossRef

22.

McQuay HJ, Sullivan AF, Smallman K, Dickenson AH. Intrathecal opioids, potency and lipophilicity. Pain. 1989;36:111–5.PubMedCrossRef

23.

Hayek SM, Joseph PN, Mekhail NA. Pharmacology of intrathecally administered agents for treatment of spasticity and pain. Semin Pain Med. 2003;1:238–53. doi:10.1016/j.spmd.2004.02.002.CrossRef

24.

Herz AT H. Activities and sites of antinociceptive action of morphine-like analgesics and kinetics of distribution following intravenous, intracerebral and intraventricular application. In: Simmonds, editor. Advances in Drug Research. London: Academic Press; 1971. p. p. 739–53.

25.

Bernards CM. Recent insights into the pharmacokinetics of spinal opioids and the relevance to opioid selection. Curr Opin Anaesthesiol. 2004;17:441–7.PubMedCrossRef

26.••

Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15:436–64. doi:10.1111/j.1525-1403.2012.00476.x. Recommendations on proper management of intrathecal drug delivery systems developed by an expert panel.PubMedCrossRef

27.

Coffey RJ, Owens ML, Broste SK, Dubois MY, Ferrante FM, Schultz DM, et al. Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesiology. 2009;111:881–91. doi:10.1097/ALN.0b013e3181b64ab8.PubMedCrossRef

28.

Coffey RJ, Owens ML, Broste SK, Dubois MY, Ferrante FM, Schultz DM, et al. Medical practice perspective: identification and mitigation of risk factors for mortality associated with intrathecal opioids for noncancer pain. Pain Med. 2010;11:1001–9. doi:10.1111/j.1526-4637.2010.00889.x.PubMedCrossRef

29.•

Hayek SM, Veizi IE, Narouze SN, Mekhail N. Age-dependent intrathecal opioid escalation in chronic noncancer pain patients. Pain Med. 2011;12:1179–89. doi:10.1111/j.1526-4637.2011.01188.x.PubMedCrossRef

30.

Veizi IE, Hayek SM, Narouze S, Pope JE, Mekhail N. Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients. Pain Med. 2011;12:1481–9. doi:10.1111/j.1526-4637.2011.01232.x.PubMedCrossRef

31.

Dominguez E, Sahinler B, Bassam D, Day M, Lou L, Racz G, et al. Predictive value of intrathecal narcotic trials for long-term therapy with implantable drug administration systems in chronic noncancer pain patients. Pain Pract. 2002;2:315–25. doi:10.1046/j.1533-2500.2002.02040.x.PubMedCrossRef

32.

Grider JSH, Etscheidt MA. Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain. Pain Physician. 2011;14:343–51.PubMed

33.•

Hamza M, Doleys D, Wells M, Weisbein J, Hoff J, Martin M. A prospective study evaluating the efficacy of opioid cessation and the use of low-dose intrathecal opioid management of noncancer pain.

34.

Deer T, Krames ES, Hassenbusch S, Burton A, Caraway D, Dupen S, et al. Management of Intrathecal Catheter-Tip Inflammatory Masses: an updated 2007 consensus statement from an expert panel. Neuromodulation. 2008;11:77–91. doi:10.1111/j.1525-1403.2008.00147.x.PubMedCrossRef

35.

Allen JW, Horais KA, Tozier NA, Wegner K, Corbeil JA, Mattrey RF, et al. Time course and role of morphine dose and concentration in intrathecal granuloma formation in dogs: a combined magnetic resonance imaging and histopathology investigation. Anesthesiology. 2006;105:581–9.PubMedCrossRef

36.

Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, et al. Polyanalgesic Consensus Conference — 2012: consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). Neuromodulation. 2012;15:483–95. doi:10.1111/j.1525-1403.2012.00449.x. discussion 96.PubMedCrossRef

37.

Tomycz ND, Ortiz V, McFadden KA, Urgo L, Moossy JJ. Management of symptomatic intrathecal catheter-associated inflammatory masses. Clin Neurol Neurosurg. 2012;114:190–5.

38.

Boswell MV, Iacono RP, Guthkelch AN. Sites of action of subarachnoid lidocaine and tetracaine: observations with evoked potential monitoring during spinal cord stimulator implantation. Reg Anesth. 1992;17:37–42.PubMed

39.

Tejwani GA, Rattan AK, McDonald JS. Role of spinal opioid receptors in the antinociceptive interactions between intrathecal morphine and bupivacaine. Anesth Analg. 1992;74:726–34.PubMedCrossRef

40.

Penning JP, Yaksh TL. Interaction of intrathecal morphine with bupivacaine and lidocaine in the rat. Anesthesiology. 1992;77:1186–2000.PubMedCrossRef

41.

Ortner CM, Posch M, Roessler B, Faybik P, Rutzler K, Grabovica J, et al. On the ropivacaine-reducing effect of low-dose sufentanil in intrathecal labor analgesia. Acta Anaesthesiol Scand. 2010;54:1000–6. doi:10.1111/j.1399-6576.2010.02254.x.PubMedCrossRef

42.

Parpaglioni R, Baldassini B, Barbati G, Celleno D. Adding sufentanil to levobupivacaine or ropivacaine intrathecal anaesthesia affects the minimum local anaesthetic dose required. Acta Anaesthesiol Scand. 2009;53:1214–20. doi:10.1111/j.1399-6576.2009.02033.x.PubMedCrossRef

43.

Levin A, Datta S, Camann WR. Intrathecal ropivacaine for labor analgesia: a comparison with bupivacaine. Anesth Analg. 1998;87:624–7.PubMed

44.

van Dongen RT, Crul BJ, van Egmond J. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain. 1999;15:166–72.PubMedCrossRef

45.

Mironer YE, Haasis JC, Chapple I, Brown C, Satterthwaite JR. Efficacy and safety of intrathecal opioids/bupivacaine mixture in chronic nonmalignant pain: a double blind, randomized, crossover, multicenter study by the National Forum of Independent Pain Clinicians (NFIPC). Neuromodulation. 2002;5:208–13.PubMedCrossRef

46.

Zhong Z, Qulian G, Yuan Z, Wangyuan Z, Zhihua S. Repeated intrathecal administration of ropivacaine causes neurotoxicity in rats. Anaesth Intensive Care. 2009;37:929–36.PubMed

47.

Malinovsky JM, Charles F, Baudrimont M, Pereon Y, Le Corre P, Pinaud M, et al. Intrathecal ropivacaine in rabbits: pharmacodynamic and neurotoxicologic study. Anesthesiology. 2002;97:429–35.PubMedCrossRef

48.

Yamashita A, Matsumoto M, Matsumoto S, Itoh M, Kawai K, Sakabe T. A comparison of the neurotoxic effects on the spinal cord of tetracaine, lidocaine, bupivacaine, and ropivacaine administered intrathecally in rabbits. Anesth Analg. 2003;97:512–9. table of contents.PubMedCrossRef

49.

Sjoberg M, Nitescu P, Appelgren L, Curelaru I. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg/mL. Anesthesiology. 1994;80:284–97.PubMedCrossRef

50.

Nitescu P, Dahm P, Appelgren L, Curelaru I. Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treatment of "refractory" nonmalignant pain. Clin J Pain. 1998;14:17–28.PubMedCrossRef

51.

McGivern JG. Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr Dis Treat. 2007;3:69–85.PubMedCentralPubMedCrossRef

52.

Wermeling D, Drass M, Ellis D, Mayo M, McGuire D, O'Connell D, et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol. 2003;43:624–36.PubMed

53.

Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291:63–70. doi:10.1001/jama.291.1.63.PubMedCrossRef

54.

Wallace MS, Charapata SG, Fisher R, Byas-Smith M, Staats PS, Mayo M, et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation. 2006;9:75–86. doi:10.1111/j.1525-1403.2006.00055.x.PubMedCrossRef

55.

Rauck RL, Wallace MS, Leong MS, Minehart M, Webster LR, Charapata SG, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006;31:393–406. doi:10.1016/j.jpainsymman.2005.10.003.PubMedCrossRef

56.

Wallace MS, Rauck R, Fisher R, Charapata SG, Ellis D, Dissanayake S. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth Analg. 2008;106:628–37. doi:10.1213/ane.0b013e3181606fad.PubMedCrossRef

57.

Maier C, Gockel HH, Gruhn K, Krumova EK, Edel MA. Increased risk of suicide under intrathecal ziconotide treatment? - a warning. Pain. 2011;152:235–7. doi:10.1016/j.pain.2010.10.007.PubMedCrossRef

58.

Feng X, Zhang F, Dong R, Li W, Liu J, Zhao X, et al. Intrathecal administration of clonidine attenuates spinal neuroimmune activation in a rat model of neuropathic pain with existing hyperalgesia. Eur J Pharmacol. 2009;614:38–43. doi:10.1016/j.ejphar.2009.04.044.PubMedCrossRef

59.

Yaksh TL, Rathbun M, Jage J, Mirzai T, Grafe M, Hiles RA. Pharacology and toxicology of chronically infused epidural clonidine.HCl in dogs. Fundam Appl Toxicol. 1994;23:319–35.PubMedCrossRef

60.

Yaksh TL, Horais KA, Tozier NA, Allen JW, Rathbun M, Rossi SS, et al. Chronically infused intrathecal morphine in dogs. Anesthesiology. 2003;99:174–87.PubMedCrossRef

61.

Bevacqua BK, Fattouh M, Backonja M. Depression, night terrors, and insomnia associated with long-term intrathecal clonidine therapy. Pain Pract. 2007;7:36–8. doi:10.1111/j.1533-2500.2007.00108.x.PubMedCrossRef

62.

Belverud S, Mogilner A, Schulder M. Intrathecal pumps. Neurotherapeutics. 2008;5:114–22. doi:10.1016/j.nurt.2007.10.070.PubMedCrossRef

63.

Gerber HR. Intrathecal morphine for chronic benign pain. Best Pract Res Clin Anaesthesiol. 2003;17:429–42.PubMedCrossRef

64.

Turner JA, Sears JM, Loeser JD. Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications. Clin J Pain. 2007;23:180–95. doi:10.1097/01.ajp.0000210955.93878.44.PubMedCrossRef

65.

Brown J, Klapow J, Doleys D, Lowery D, Tutak U. Disease-specific and generic health outcomes: a model for the evaluation of long-term intrathecal opioid therapy in noncancer low back pain patients. Clin J Pain. 1999;15:122–31.PubMedCrossRef

66.

Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330:592–6. doi:10.1056/NEJM199403033300902.PubMedCrossRef

67.

Rauck RL, Cherry D, Boyer MF, Kosek P, Dunn J, Alo K. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain. 2003;4:441–7.PubMedCrossRef

68.

Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain, drug related toxicitiy, and survival. J Clin Oncol. 2002;20:4040–9.PubMedCrossRef

69.

Smith TJ, Coyne PJ, Staats PS, Deer T, Stearns LJ, Rauck RL, et al. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol. 2005;16:825–33. doi:10.1093/annonc/mdi156.PubMedCrossRef

70.

Burton AW, Rajagopal A, Shah HN, Mendoza T, Cleeland C, Hassenbusch SJ, et al. Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med. 2004;5:239–47. doi:10.1111/J.1526-4637.2004.04037.X.PubMedCrossRef

71.

Ahmed SU, Martin NM, Chang Y. Patient selection and trial methods for intraspinal drug delivery for chronic pain: a national survey. Neuromodulation. 2005;8:112–20. doi:10.1111/j.1525-1403.2005.00227.x.PubMedCrossRef

72.

Anderson VC, Burchiel KJ, Cooke B. A Prospective, randomized trial of intrathecal injection vs. epidural infusion in the selection of patients for continuous intrathecal opioid therapy. Neuromodulation. 2003;6:142–52.PubMedCrossRef

73.

Kim D, Saidov A, Mandhare V, Shuster A. Role of pretrial systemic opioid requirements, intrathecal trial dose, and nonpsychological factors as predictors of outcome for intrathecal pump therapy: one clinician's experience with lumbar postlaminectomy pain. Neuromodulation. 2011;14:165–75.

74.

Kamran S, Wright BD. Complications of intrathecal drug delivery systems. Neuromodulation. 2001;4:111–5. doi:10.1046/j.1525-1403.2001.00111.x.PubMedCrossRef

75.

Follett KA, Naumann CP. A prospective study of catheter-related complications of intrathecal drug delivery systems. J Pain Symptom Manage. 2000;19:209–15.PubMedCrossRef

76.

Follett KA, Burchiel K, Deer T, Dupen S, Prager J, Turner MS, et al. Prevention of intrathecal drug delivery catheter-related complications. Neuromodulation. 2003;6:32–41. doi:10.1046/j.1525-1403.2003.03005.x.PubMedCrossRef

77.

Deer TR, Prager J, Levy R, Burton A, Buchser E, Caraway D, et al. Polyanalgesic Consensus Conference–2012: recommendations on trialing for intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15:420–35. doi:10.1111/j.1525-1403.2012.00450.x. discussion 35.PubMedCrossRef

78.

Peerdeman SM, de Groot V, Feller RE. In situ treatment of an infected intrathecal baclofen pump implant with gentamicin-impregnated collagen fleece. J Neurosurg. 2010;112:1308–10. doi:10.3171/2009.8.JNS081692.PubMedCrossRef

79.

Diefenbeck M, Muckley T, Hofmann GO. Prophylaxis and treatment of implant-related infections by local application of antibiotics. Injury. 2006;37 Suppl 2:S95–104. doi:10.1016/j.injury.2006.04.015.PubMedCrossRef

80.

Ilias W, le Polain B, Buchser E, Demartini L; oPTIMa study group. Patient-controlled analgesia in chronic pain patients: experience with a new device designed to be used with implanted programmable pumps. Pain Pract. 2008;8:164–70.

81.

Maeyaert J, Buchser E, Van Buyten JP, Rainov NG, Becker R. Patient-controlled analgesia in intrathecal therapy for chronic pain: safety and effective operation of the Model 8831 Personal Therapy Manager with a Pre-implanted SynchroMed Infusion System. Neuromodulation. 2003;6:133–41. doi:10.1046/j.1525-1403.2003.03021.x.PubMedCrossRef

82.

Hayek SM. Intrathecal "microdosing": reality or artifact? Pain Med. 2012;13:1664–5. doi:10.1111/j.1526-4637.2012.01507.PubMedCrossRef

83.

Brodner RA, Taub A. Chronic pain exacerbated by long-term narcotic use in patients with nonmalignant disease: clinical syndrome and treatment. Mt Sinai J Med. 1978;45:233–7.PubMed

84.

Taylor CB, Zlutnick SI, Corley MJ, Flora J. The effects of detoxification, relaxation, and brief supportive therapy on chronic pain. Pain. 1980;8:319–29.PubMedCrossRef

Title: Intrathecal Therapy for Chronic Pain: Current Trends and Future Needs
Authors: Salim M. Hayek
Michael C. Hanes
Publication date: 01-01-2014
Publisher: Springer US
Published in: Current Pain and Headache Reports / Issue 1/2014
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI: https://doi.org/10.1007/s11916-013-0388-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Intrathecal Therapy for Chronic Pain: Current Trends and Future Needs

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Economic Burden and Costs of Chronic Migraine

Cervical Radicular Pain: The Role of Interlaminar and Transforaminal Epidural Injections

Erratum to: Why does Sleep Stop Migraine?

Cancer-Induced Oxidative Stress and Pain

Historical and Present State of Neuromodulation in Chronic Pain

An Update on Botulinum Toxin A Injections of Trigger Points for Myofascial Pain